Synapse - Thoracic Oncology

Results (3394)

TATTON phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

Meeting Abstract

Sequist, L. V.; Lee, J. S.; Han, J. Y.; Su, W. C.; Yang, J. C. H.; Yu, H.; Ottesen, L. H.; Verheijen, R. B.; Mellemgaard, A.; Wessen, J.; more...
Cancer Research (2019)

Fulltext@MSK | Save

A phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer

Meeting Abstract

Reckamp, K. L.; Akerley, W.; Edelman, M. J.; Halmos, B.; He, K.; Johnson, M.; Mudad, R.; Neal, J. W.; Owonikoko, T. K.; Patel, J. D.; more...
Cancer Research (2019)

Fulltext@MSK | Save

Identification of gene signatures associated with response in a phase II trial of entinostat (ENT) plus pembrolizumab (PEMBRO) in non-small cell lung cancer (NSCLC) patients whose disease has progressed on or after anti-PD-(L)1 therapy

Meeting Abstract

Ordentlich, P.; Wang, L.; Tamang, D.; Sullivan, A. H.; Church, S. E.; Rozelle, D.; Meyers, M. L.; Ramalingam, S. S.; Hellmann, M. D.
Cancer Research (2019)

Fulltext@MSK | Save

Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the phase Ib TATTON study

Meeting Abstract

Ramalingam, S. S.; Saka, H.; Ahn, M. J.; Yu, H.; Horn, L.; Hida, T.; Cantarini, M.; Verheijen, R.; Wessen, J.; Oxnard, G.; more...
Cancer Research (2019)

Fulltext@MSK | Save

Inherited truncating RAD52 variant discovered using integrated germline-somatic analysis predicts clinical outcome in patients with lung cancers

Meeting Abstract

Mukherjee, S.; Srinivasan, P.; Bandlamudi, C.; Hellmann, M. D.; Ravichandran, V.; Selvan, M. E.; Kemel, Y.; Mandelker, D.; Zauderer, M.; Walsh, M.; more...
Cancer Research (2019)

Fulltext@MSK | Save

Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)

Meeting Abstract

Hyman, D.; Kummar, S.; Farago, A.; Geoerger, B.; Mau-Sorensen, M.; Taylor, M.; Garralda, E.; Nagasubramanian, R.; Natheson, M.; Song, L.; more...
Cancer Research (2019)

Fulltext@MSK | Save

KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancer

Meeting Abstract

Gutierrez, M.; Hellmann, M. D.; Gubens, M.; Aggarwal, C.; Tan, D. S. W.; Felip, E.; Chiu, J. W. Y.; Lee, J. S.; Yang, J. C. H.; Garon, E.; more...
Cancer Research (2019)

Fulltext@MSK | Save

Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: Dose escalation

Meeting Abstract

Hamilton, E.; Falchook, G. S.; Wang, J. S.; Fu, S.; Oza, A.; Karen, S.; Imedio, E. R.; Kumar, S.; Ottesen, L.; Mugundu, G. M.; more...
Cancer Research (2019)

Fulltext@MSK | Save

Characterization of SLFN11 protein expression in circulating tumor cells (CTCs) of patients with metastatic castration resistant prostate cancer (mCRPC) prior to platinum based chemotherapy

Meeting Abstract

Fernandez, L.; Poirier, J.; Rodriguez, A.; Hulling, M.; Richardson, R.; Sutton, R.; Jiles, R.; Schonhoft, J.; Lee, J.; Ebrahim, N.; more...
Cancer Research (2019)

Fulltext@MSK | Save

Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2

Meeting Abstract

Drilon, A.; Barlesi, F.; De Braud, F.; Cho, B. C.; Ahn, M. J.; Siena, S.; Krebs, M. G.; Lin, C. C.; John, T.; Tan, D. S. W.; more...
Cancer Research (2019)

Fulltext@MSK | Save